Knight Therapeutics Company Executives

Knight Therapeutics Management Team Effectiveness

As of the 19th of January 2026, Return On Capital Employed is likely to grow to 0.01, while Return On Tangible Assets are likely to drop 0.01. At this time, Knight Therapeutics' Total Current Assets are very stable compared to the past year. As of the 19th of January 2026, Intangibles To Total Assets is likely to grow to 0.36, while Total Assets are likely to drop about 961.1 M. Knight Therapeutics' management efficiency ratios could be used to measure how well Knight Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2026, Common Stock Shares Outstanding is likely to grow to about 126 M. Also, Net Income Applicable To Common Shares is likely to grow to about 5.2 MKnight Therapeutics maintains a total of 99.29 Million outstanding shares. Knight Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Knight Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Knight Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Knight Therapeutics Workforce Comparison

Knight Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01.

Knight Therapeutics Benchmark Summation

Knight Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Knight Therapeutics often depends on how effective the management is. Knight Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Knight management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Knight management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.